ong term prospective observational cohort study of the safety and efficacy of golimumab in the daily clinical practice of rheumatoid arthritis with emphasis on the lipid profile
Phase 4
Recruiting
- Conditions
- inflammatory rheumatic disease1000381610023213
- Registration Number
- NL-OMON36406
- Lead Sponsor
- Jan van Breemen Instituut
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
patients with rheumatoid arthritis in whom golimumab treatment is started.
written informed consent.
Exclusion Criteria
contraindications against golimumab treatment
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Efficacy will be determined in comparison to baseline by measuring disease<br /><br>activity, radiological progression and functional capacity during follow-up.<br /><br>Safety will be determined by the occurrence of side effects. Changes in lipid<br /><br>profile markers during the four years of treatment will be analyzed versus<br /><br>baseline. </p><br>
- Secondary Outcome Measures
Name Time Method <p>nvt</p><br>